PKU HEALTHCARE has obtained the drug registration certificate for Apremilast Tablets
PKU HEALTHCARE has obtained the drug registration certificate for Apremilast tablets issued by the National Medical Products Administration, which includes specifications of 10mg and 30mg. Apremilast is a small molecule inhibitor targeting PDE4, primarily used for the treatment of moderate to severe plaque psoriasis, with advantages such as rapid onset, clear efficacy, and high safety
According to the Zhitong Finance APP, PKU HEALTHCARE (000788.SZ) announced that the company has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The drugs for which the registration certificate has been obtained are Apremilast tablets in two specifications (10mg and 30mg).
Apremilast is a small molecule inhibitor that specifically targets phosphodiesterase-4 (PDE4). By regulating intracellular inflammatory signaling pathways, it effectively inhibits the release of pro-inflammatory factors and increases the production of anti-inflammatory factors, thereby precisely controlling the inflammatory response. Apremilast tablets are used to treat adult patients with moderate to severe plaque psoriasis who meet the indications for phototherapy or systemic therapy, characterized by rapid onset, clear efficacy, and high safety
